IL17A and psoriasis: In conclusion, we found routine serial repeat QFT-GIT testing in patients using anti-IL-17A monoclonal antibodies for psoriasis was associated with very low seroconversion rate in Taiwan, compared to tumor necrosis factor-α (TNF-α) inhibitors (14.29%) [30] and ustekinumab, an anti-interleukin (IL)-12/23 antibody (7.3%).